Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma

Por Bauer, J, Kilic, E, Vaarwater, J, Bastian, B C, Garbe, C, de Klein, A
Publicado em 2009

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II...

Por Algazi, A P, Cha, E, Ortiz-Urda, S M, McCalmont, T, Bastian, B C, Hwang, J, Pampaloni, M H, Behr, S, Chong, K, Cortez, B, Quiroz, A, Coakley, F, Liu, S, Daud, A I
Publicado no Br J Cancer (2015)

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Por Guo, J., Carvajal, R. D., Dummer, R., Hauschild, A., Daud, A., Bastian, B. C., Markovic, S. N., Queirolo, P., Arance, A., Berking, C., Camargo, V., Herchenhorn, D., Petrella, T. M., Schadendorf, D., Sharfman, W., Testori, A., Novick, S., Hertle, S., Nourry, C., Chen, Q., Hodi, F. S.
Publicado no Ann Oncol (2017)